低剂量率近距离放疗作为局限性和局部晚期前列腺癌主要治疗的系统综述:经济学评价
该研究系统综述了2008至2023年比较低剂量率近距离放疗(LDR-BT)与其他治疗方式成本效果的经济学评价。共纳入14项研究,异质性较大;在认为标准治疗肿瘤学结局等效的前提下,LDR-BT在多数研究中较其他放疗方式、根治性前列腺切除术和主动监测更具成本效果。
要点
- 在12项研究中,9项(75%)显示LDR-BT是最具成本效果的放疗类型。
- 在9项研究中,6项(67%)显示LDR-BT比根治性前列腺切除术更具成本效果。
- 在5项研究中,3项(60%)显示LDR-BT比主动监测更具成本效果,取决于时间范围。
核心结论
- 现有卫生经济学证据提示LDR-BT具有显著的成本优势,在提供基于价值的前列腺癌诊疗中可发挥重要作用。
研究设计与样本
- 系统综述,检索MEDLINE、EMBASE和Tufts医学中心成本效果分析(CEA)注册库中2008年至2023年发表的研究(Prospero方案CRD42023-442027)。
- 两名评价者独立根据商定的纳入和排除标准筛选标题和摘要,随后进行全文筛选。
- 使用Drummond清单对纳入研究进行质量评价。
- 筛选453条记录后,36条被寻求获取全文,最终纳入14项合格研究。
主要发现
- 纳入的14项研究中,11项比较低危和/或有利中危前列腺癌的治疗,2项比较不利中危和/或高危疾病的治疗选择,1项分析两个风险组的治疗。
- 在人群、视角、时间范围、成本和结局数据方面存在相当大的异质性。
- 若认为标准治疗方法的肿瘤学结局等效,LDR-BT在12项研究中的9项(75%)是最具成本效果的放疗类型。
- LDR-BT在9项研究中的6项(67%)比根治性前列腺切除术更具成本效果。
- LDR-BT在5项研究中的3项(60%)比主动监测更具成本效果,取决于时间范围。
关键数值与推荐
- LDR-BT在所有4项(100%)比较研究中比高剂量率近距离放疗(HDR-BT)更具成本效果。
- 总体而言,LDR-BT在14项研究中的7项(50%)是所有主动治疗选择中成本最低的。
局限性
- 纳入研究在人群、视角、时间范围、成本和结局数据方面存在相当大的异质性。
- 未来如果放疗倾向于超低分割策略如立体定向体部放疗(SBRT)和HDR-BT减少分割,LDR-BT的这些优势可能受到挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study supports a value-based approach to prostate cancer (PCa) treatment by systematically reviewing economic evaluations that compare the cost and cost-effectiveness of low-dose-rate brachytherapy (LDR-BT) with that of other treatment options for localised and locally advanced PCa. METHODS: Studies published between 2008 and 2023 were searched for in MEDLINE, EMBASE and Tufts Medical Center's Cost-Effectiveness Analysis (CEA) Registry (Prospero protocol CRD42023-442027). Two reviewers independently screened the title and abstracts based on agreed inclusion and exclusion criteria, followed by full-text screening. The Drummond checklist was used to critically appraise the quality of the included studies. RESULTS: After screening 453 records, 36 were sought for retrieval and 14 eligible studies included. Of them, 11 compared treatments for low- and/or favourable intermediate-risk PCa, 2 compared options for unfavourable intermediate- and/or high-risk disease and 1 analysed treatments for both risk groups. Considerable heterogeneity was seen in the populations, perspectives, time horizons, costs and outcomes data used. If the oncological outcomes of standard treatment approaches are considered equivalent, LDR-BT was the most cost-effective type of radiation therapy (RT) in 9 (75%) of 12 studies, was more cost-effective than radical prostatectomy (RP) in 6 (67%) of 9 studies and, depending on the time horizon, was more cost-effective than active surveillance (AS) in 3 (60%) of 5 studies. LDR-BT was more cost-effective than high-dose-rate brachytherapy (HDR-BT) in all 4 (100%) of the studies that made this comparison and, overall, LDR-BT was the least costly of all active treatment options in 7 (50%) of the 14 studies. CONCLUSION: The available health economic evidence suggests that LDR-BT has significant cost advantages and an important role to play in the delivery of value-based PCa care. In the future these advantages could be challenged if radiotherapy favours ultrahypofractionated strategies such as stereotactic body radiation therapy (SBRT) and reduced fractionation in HDR-BT.
引用
- Stanberry B, Webber-Jones N. Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations. Prostate Cancer Prostatic Dis. 2024. PMID: 38480973. doi:10.1038/s41391-024-00817-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。